Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

31.73 -0.62 (-1.92%)
Streaming Delayed Price Updated: 10:18 AM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
News headline image
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
News headline image
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? ↗
Via The Motley Fool
News headline image
Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' ↗
Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval. 
Via Benzinga
Topics Intellectual Property
News headline image
MarketBeat Week in Review – 02/03 - 02/07
Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets. 
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
News headline image
Teva Pharmaceutical Indus Options Trading: A Deep Dive into Market Sentiment ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Teva Pharmaceutical Indus Stock ↗
 
Via Benzinga
News headline image
Neurocrine Biosciences Reports Mixed Q4 ↗
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. 
Via The Motley Fool
News headline image
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp? 
Via MarketBeat
News headline image
NVIDIA, Teva Pharmaceutical And UPS Are Among Top Large Cap Losers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio? ↗
Discover the latest trends with last week's worst-performing large-cap stocks, including Manhattan Associates' steep decline following reduced financial guidance and the broader impact of China's... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Why Teva Pharmaceutical Stock Is Sinking Today ↗
Via The Motley Fool
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Peering Into Teva Pharmaceutical Indus's Recent Short Interest ↗
 
Via Benzinga
News headline image
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript ↗
TEVA earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet ↗
 
Via Benzinga
News headline image
Stocks Tick Down Ahead Of Fed Meeting, Nvidia Jitters Resume, Trump Media Rallies: What's Driving Markets Wednesday? ↗
Caution dominates Wednesday's midday trading session in New York as investors anxiously await the Federal Open Market Committee decision at 2 p.m. ET. 
Via Benzinga
Topics Economy Government
News headline image
Stocks Scatter As Investors Prepare For Fed Remarks ↗
Stocks are mixed this afternoon, as investors await an interest rate update from the Federal Reserve's first policy meeting of 2025. 
Via Talk Markets
Topics Economy Stocks / Equities
News headline image
Nasdaq Down Over 100 Points; Corning Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Teva Pharmaceutical Posts Lower Revenue. Stock Slips. ↗
Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue. 
Via Investor's Business Daily
News headline image
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On? ↗
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,... 
Via Benzinga
News headline image
Manhattan Associates, LendingClub And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data ↗
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
From Alvotech
Via GlobeNewswire
News headline image
Earnings Scheduled For January 29, 2025 ↗
 
Via Benzinga
News headline image
FDA Warns Of Severe Allergic Reaction Risk With Teva's Multiple Sclerosis Drug ↗
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention. 
Via Benzinga
News headline image
Promising Signs: TEVA PHARMACEUTICAL-SP ADR Setting the Stage for a Breakout. ↗
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) has a good technical rating of 10 out of 10 and could possibly break out. 
Via Chartmill
News headline image
Teva Challenges Drug Price Law's Impact On Innovation, Generics ↗
Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, and innovation, disrupting healthcare balance. 
Via Benzinga
Topics Economy
News headline image
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations ↗
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.